$BPTH
BIO-PATH HOLDINGS, INC.

2019 Q1 Form 10-K Financial Statement

#000114420419014855 Filed on March 19, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.120M $800.0K $3.380M
YoY Change 13.13% -2.44% -3.98%
% of Gross Profit
Research & Development $398.0K $500.0K $4.603M
YoY Change -57.3% -64.03% -16.0%
% of Gross Profit
Depreciation & Amortization $66.00K $110.0K $265.0K
YoY Change 0.0% 10.0% 5.58%
% of Gross Profit
Operating Expenses $1.520M $1.300M $8.590M
YoY Change -20.79% -41.18% -4.59%
Operating Profit -$1.520M -$8.590M
YoY Change -20.79% -4.19%
Interest Expense $10.00K $0.00 $10.00K
YoY Change 0.0%
% of Operating Profit
Other Income/Expense, Net $8.000K $0.00 $7.000K
YoY Change 166.67% -99.64%
Pretax Income -$1.510M -$1.910M -$8.583M
YoY Change -21.35% -11.98% 22.21%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.512M -$1.910M -$8.583M
YoY Change -21.09% -11.98% 22.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$888.2K -$2.809M -$14.30M
COMMON SHARES
Basic Shares Outstanding 2.507M 13.60M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.28M $1.000M $1.000M
YoY Change 350.47% -83.25% -83.25%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $1.163M $593.0K $1.130M
YoY Change -26.86% 67.99% -23.13%
Inventory
Prepaid Expenses $427.0K $332.0K
Receivables
Other Receivables
Total Short-Term Assets $20.87M $1.929M $2.140M
YoY Change 255.47% -74.06% -71.24%
LONG-TERM ASSETS
Property, Plant & Equipment $340.0K $406.0K $410.0K
YoY Change -43.8% -37.92% -36.92%
Goodwill
YoY Change
Intangibles $0.00
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $453.0K $406.0K $410.0K
YoY Change -65.94% -71.47% -71.13%
TOTAL ASSETS
Total Short-Term Assets $20.87M $1.929M $2.140M
Total Long-Term Assets $453.0K $406.0K $410.0K
Total Assets $21.32M $2.335M $2.550M
YoY Change 196.1% -73.64% -71.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $607.0K $813.0K $590.0K
YoY Change 333.57% 1463.46% 1080.0%
Accrued Expenses $456.0K $304.0K $740.0K
YoY Change -42.28% -58.86% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.117M $1.117M $1.330M
YoY Change 20.11% 41.21% 68.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $60.00K $0.00 $0.00
YoY Change
Total Long-Term Liabilities $60.00K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.117M $1.117M $1.330M
Total Long-Term Liabilities $60.00K $0.00 $0.00
Total Liabilities $1.176M $1.117M $1.330M
YoY Change 26.45% 41.21% 68.35%
SHAREHOLDERS EQUITY
Retained Earnings -$49.25M -$47.74M
YoY Change 21.92%
Common Stock $3.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.14M $1.218M $1.220M
YoY Change
Total Liabilities & Shareholders Equity $21.32M $2.335M $2.550M
YoY Change 196.1% -73.64% -71.22%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$1.512M -$1.910M -$8.583M
YoY Change -21.09% -11.98% 22.21%
Depreciation, Depletion And Amortization $66.00K $110.0K $265.0K
YoY Change 0.0% 10.0% 5.58%
Cash From Operating Activities -$2.008M -$1.280M -$6.124M
YoY Change 20.67% -42.6% -23.04%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $17.00K
YoY Change -100.0% -96.84%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$17.00K
YoY Change -100.0% -96.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.41M $1.180M
YoY Change -66.92%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.28M 0.000 1.180M
YoY Change -100.0% -76.79%
NET CHANGE
Cash From Operating Activities -2.008M -1.280M -6.124M
Cash From Investing Activities 0.000 0.000 -17.00K
Cash From Financing Activities 20.28M 0.000 1.180M
Net Change In Cash 18.27M -1.280M -4.961M
YoY Change -1186.97% -195.52% 45.48%
FREE CASH FLOW
Cash From Operating Activities -$2.008M -$1.280M -$6.124M
Capital Expenditures $0.00 $0.00 $17.00K
Free Cash Flow -$2.008M -$1.280M -$6.141M
YoY Change 19.45% -42.6% -27.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-12000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6124000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7957000
CY2018Q4 us-gaap Cash
Cash
1004000
CY2017Q4 us-gaap Cash
Cash
5965000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
332000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1117000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
593000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
353000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1929000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
7435000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
998000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
984000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
592000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
330000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
406000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
654000
CY2018Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
0
CY2017Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2500000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
0
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1731000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
769000
CY2018Q4 us-gaap Assets
Assets
2335000
CY2017Q4 us-gaap Assets
Assets
8858000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
813000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
52000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
304000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
739000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1117000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
791000
CY2018Q4 us-gaap Liabilities
Liabilities
1117000
CY2017Q4 us-gaap Liabilities
Liabilities
791000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48957000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47223000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47740000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39157000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1218000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
8067000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2335000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8858000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
680
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
567
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000
CY2018 us-gaap Revenues
Revenues
0
CY2017 us-gaap Revenues
Revenues
37000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4603000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5480000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3379000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3523000
CY2018 us-gaap Operating Expenses
OperatingExpenses
8590000
CY2017 us-gaap Operating Expenses
OperatingExpenses
9003000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-8590000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-8966000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2374000
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-440000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1943000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-8583000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-7023000
CY2018 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
CY2017 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1038000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8583000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8061000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.38
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.99
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
597000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
504000
CY2018 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
608000
CY2017 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2018 us-gaap Adjustment For Amortization
AdjustmentForAmortization
161000
CY2017 us-gaap Adjustment For Amortization
AdjustmentForAmortization
160000
CY2018 us-gaap Depreciation
Depreciation
265000
CY2017 us-gaap Depreciation
Depreciation
251000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
554000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
793000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2374000
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-440000
CY2018 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-785000
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
741000
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
240000
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-549000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
326000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
538000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-538000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1180000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3567000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1518000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1180000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5085000
CY2018 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-4961000
CY2017 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-3410000
CY2016Q4 us-gaap Cash
Cash
9375000
CY2018 bpth Warrants Transferred To Equity Upon Modification
WarrantsTransferredToEquityUponModification
0
CY2017 bpth Warrants Transferred To Equity Upon Modification
WarrantsTransferredToEquityUponModification
797000
CY2018 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0
CY2017 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
175000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
8240000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3567000
CY2017 bpth Stock Issue During Period Value Warrants Exercised
StockIssueDuringPeriodValueWarrantsExercised
1518000
CY2017 bpth Adjustments To Additional Paid In Capital Warrants Transferred To Equity Upon Modification
AdjustmentsToAdditionalPaidInCapitalWarrantsTransferredToEquityUponModification
797000
CY2017 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
175000
CY2017 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
793000
CY2017 bpth Adjustments To Additional Paid In Capital Deemed Dividend
AdjustmentsToAdditionalPaidInCapitalDeemedDividend
-1038000
CY2017 bpth Adjustments To Additional Paid In Capital Warrant Exercise Price Modification
AdjustmentsToAdditionalPaidInCapitalWarrantExercisePriceModification
1038000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1180000
CY2018 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
554000
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
29412
CY2017Q2 bpth Classofwarrantorrightexercisablenumber
Classofwarrantorrightexercisablenumber
22059
CY2017Q2 bpth Class Of Warrant Or Right Exercised Number
ClassOfWarrantOrRightExercisedNumber
559
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk &#8212; </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject us to a significant concentration of credit risk consist of cash. The Company maintains its cash balances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) up to $250,000. As a result, as of December 31, 2018, approximately $0.8 million of our cash balances was not covered by the FDIC. As of December 31, 2017, we had approximately $6.0 million in cash on-hand, of which approximately $5.7 million was not covered by the FDIC. To date, the Company has not incurred any losses on its cash balances.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 bpth Research And Development Costs Expenses
ResearchAndDevelopmentCostsExpenses
4600000
CY2017 bpth Research And Development Costs Expenses
ResearchAndDevelopmentCostsExpenses
5500000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15286
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28102
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates &#8212;</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (&#8220;U.S.&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends as well as on various other assumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from the Company&#8217;s estimates. These estimates include accrued clinical trial costs, stock-based compensation expense, valuation of warrants and valuation of deferred tax assets.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 bpth Development Project Service Evaluation Exchange Cost
DevelopmentProjectServiceEvaluationExchangeCost
50000
CY2017Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
800000
CY2017Q4 us-gaap Other Finite Lived Intangible Assets Gross
OtherFiniteLivedIntangibleAssetsGross
2500000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1100000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
300000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
100000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
100000
CY2018Q4 bpth Accrued Clinical And Preclinical Expenses
AccruedClinicalAndPreclinicalExpenses
100000
CY2018Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
100000
CY2018Q4 bpth Accrued Legal And Professional Fee
AccruedLegalAndProfessionalFee
100000
CY2017Q4 bpth Accrued Clinical And Preclinical Expenses
AccruedClinicalAndPreclinicalExpenses
400000
CY2017Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
100000
CY2017Q4 bpth Accrued License Maintenance Fee
AccruedLicenseMaintenanceFee
100000
CY2017Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
112.60
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
31000
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2906000
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-2374000
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-357000
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-175000
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.55
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
120.00
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
60000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
600000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
800000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
800000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0270
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0206
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.99
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
32000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
232.00
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.60
CY2018 bpth Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantedinperiodcontractualterm
Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantedinperiodcontractualterm
P9Y3M18D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
15000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
267.20
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
37000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
124.60
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
15000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
181.00
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
35000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
266.00
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M12D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2241
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
150.00
CY2017 bpth Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantedinperiodcontractualterm
Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantedinperiodcontractualterm
P9Y3M18D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
330.00
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
426.00
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
31000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
230.00
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y9M18D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
28000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
214.00
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y3M18D
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2017Q2 bpth Classofwarrantorrightexercisablenumber
Classofwarrantorrightexercisablenumber
22059
CY2017Q2 bpth Class Of Warrant Or Right Exercised Number
ClassOfWarrantOrRightExercisedNumber
559
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
183000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P4Y7M6D
CY2018 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Option Outstanding Weighted Average Exercise Price Per Share
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionOutstandingWeightedAverageExercisePricePerShare
52.24
CY2018Q4 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableNumberOfShares
63000
CY2018 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Weighted Average Exercise Price Per Share
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePricePerShare
114.28
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
82000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
31000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
31000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
10000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
154000
CY2018Q4 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
1000000
CY2018Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
35000
CY2017Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
47000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
35800000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8583000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7023000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6750000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1802000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2388000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2295000
CY2018 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
47000
CY2017 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
86000
CY2016 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
117000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
238000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
283000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
252000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1845000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1447000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3001000
CY2018 bpth Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant
0
CY2017 bpth Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant
658000
CY2016 bpth Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant
582000
CY2018 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
0
CY2017 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
5000
CY2016 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
6000
CY2018 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
2000
CY2017 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-252000
CY2016 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
5000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
146000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2018 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
0
CY2017 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
4937000
CY2016 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
12000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
0
CY2018Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
15000
CY2017Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
17000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9191000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7516000
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018Q4 bpth Deferred Tax Assets Technology Licenses
DeferredTaxAssetsTechnologyLicenses
0
CY2017Q4 bpth Deferred Tax Assets Technology Licenses
DeferredTaxAssetsTechnologyLicenses
36000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1780000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1542000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
310000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
387000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
50000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
15000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11363000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9518000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11363000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9518000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
8000000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
4900000
CY2018 bpth Research And Development Tax Credit Carryforward Expiration Period
ResearchAndDevelopmentTaxCreditCarryforwardExpirationPeriod
P2028Y
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11400000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9500000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
567
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
680
CY2018 us-gaap General Discussion Of Pension And Other Postretirement Benefits
GeneralDiscussionOfPensionAndOtherPostretirementBenefits
We make matching contributions equal to 100% of the first 3% and 50% of the next 2% of each employee&#8217;s base salary up to the allowable amount which is fully vested on the date the matching contributions are made.
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
43800000
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
15884741
CY2018 dei Trading Symbol
TradingSymbol
BPTH
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2507239
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17000000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
100000

Files In Submission

Name View Source Status
0001144204-19-014855-index-headers.html Edgar Link pending
0001144204-19-014855-index.html Edgar Link pending
0001144204-19-014855.txt Edgar Link pending
0001144204-19-014855-xbrl.zip Edgar Link pending
bpth-20181231.xml Edgar Link completed
bpth-20181231.xsd Edgar Link pending
bpth-20181231_cal.xml Edgar Link unprocessable
bpth-20181231_def.xml Edgar Link unprocessable
bpth-20181231_lab.xml Edgar Link unprocessable
bpth-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv515879_10k.htm Edgar Link pending
tv515879_ex23-1.htm Edgar Link pending
tv515879_ex31.htm Edgar Link pending
tv515879_ex32.htm Edgar Link pending
tv515879_ex4-15.htm Edgar Link pending
tv515879_img01.jpg Edgar Link pending
tv515879_img02.jpg Edgar Link pending
tv515879_img03.jpg Edgar Link pending
tv515879_img04.jpg Edgar Link pending
tv515879_img05.jpg Edgar Link pending
tv515879_img06.jpg Edgar Link pending
tv515879_img07.jpg Edgar Link pending
tv515879_img08.jpg Edgar Link pending
tv515879_img09.jpg Edgar Link pending